

A BETTER APPROACH FOR BETTER CLINICAL TRIALS

NSCLC occurs most often in women and men over the age of 70 who have a history of smoking. Oncology studies like NSCLC are complex, and often involve multiple cohorts, diverse tumor types, scattered sites, and expensive medications. More importantly, NSCLC patients face debilitating symptoms that can make participation in studies difficult. That's where Signant Health's evidence generation solutions can help.

IMPLEMENT eCOA IN JUST 8 WEEKS

With over 20 years of experience supporting NSCLC trials, we created a pre-configured eCOA solution that incorporates pre-validated library instruments, scientific design best practices, oncology-specific features as well as our unrivaled global logistics and support.

It's 33% faster than other eCOA options and will reduce your costs by 20%.

PLACE THE PATIENT FIRST

Our patient-focused approach is embedded in everything from the software to the eCOA instruments' overall designs. For example, thoughtfully migrating instrument layouts to electronic formats to ensure ease of use, such as larger, well-spaced buttons compensate for treatment-related finger numbness.

GAIN RICHER INSIGHTS

With our sensors and wearables, you can collect objective data on sleep and activity patterns, for enhanced insight into the post-treatment recovery associated with each treatment cycle. Pair with our eCOA for a continuous, real-time view of each patients' health status.

At Signant Health, our suite of SmartSignals™ solutions were designed specifically to meet the needs of NSCLC sponsors, sites, and patients alike. To advance treatments, NSCLC studies must be run using today's latest technology.

SIMPLIFY THE CONSENT PROCESS

Signant Health's SmartSignals™ eConsent uses engaging multimedia to convey complex information and allows patients to flag sections they have questions on. The solution also handles the multiple consents and protocol amendments common in NSCLC trials, limiting the risk of inspection findings.

OPTIMIZE SUPPLY MANAGEMENT

Our SmartSignals™ RTSM solution uses proprietary algorithms to optimize drug supplies for the different, complex study designs associated with NSCLC trials, and applies randomization adaptations seamlessly.

DIGITALIZE THE ENTIRE PROCESS

While all of our solutions can be used as standalone tools, they seamlessly integrate with one another to further enhance the accuracy and efficiency of your NSCLC study.

COMMON LIBRARY MEASURES USED IN NSCLC

- EORTC QLQ-C30, LC13, LC29
- Mood: HADS, PHQ-9
- FACT G, L
- AEs: PRO-CTCAE
- PROMIS Fatigue, Global Health, Physical function, Sleep disturbance
- Generic: ST-36, EQ-5D

ASK US FOR A COMPLETE LIST.

SIGNANT'S NSCLC EXPERIENCE IN THE PAST 5 YEARS

Phases



60
Trials



53
Languages



51
Countries



19,000+
Patients



5,712
Sites

SMARTSIGNALS™ TRIAL SOLUTIONS

PRE-CONFIGURED eCOA | RTSM | eCONSENT | ACTIVITY & SLEEP MONITORING

MEET THE EXPERTS

Discuss your next NSCLC trial with our subject matter experts, and we'll tailor our eCOA solution to fit your needs.



BILL BYROM, PhD

VP Product Intelligence & Positioning

Dr. Byrom has worked in the Pharmaceutical industry for 30 years and is the author of over 70 publications and two industry textbooks on electronic patient-reported outcomes (ePRO).



TODD EVERHART, MD

Clinical VP Internal Medicine

Dr. Everhart is board-certified in internal medicine and a fellow of the American College of Physicians with over 23 years of experience in the practice of medicine and over 12 years of experience in clinical development.



FLORENCE MOWLEM, PhD

Scientific Advisor

Dr. Mowlem works across therapeutic areas and is also the eCOA Science Oncology lead; her most recent scientific work includes understanding how the unique needs of oncology patients can impact their use of electronic devices in oncology trials.

CONTACT US TO LEARN HOW SIGNANT HEALTH CAN SUPPORT YOUR NEXT STUDY.